Table 4 In vivo anti-cancer activity of identified GpM components
From: Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)
| Component | Animal model | Anti-cancer activitya | Reference |
|---|---|---|---|
| Gypenosides | Nude mice: xenografted with human oral cancer SAS cells | 65.76 % (tumor size, 20 mg/kg for 28 days) | [89] |
| Gypenosides | BALB/c mice: injected with human leukemia WEHI-3 cells |
150 % (survival rate, 2 mg/kg for 2 weeks) 175 % (survival rate, 4 mg/kg for 2 weeks) | [90] |
| Gypenosides | Nude mice: xenografted with human leukemia HL-60 cells | 44 % (tumor size, 20 mg/kg for 28 days) | [91] |
| Gypenosides | BALB/c mice: xenografted with murine S180 sarcoma cells | 39.57 % (tumor size, 30 mg/kg for 4 days) | [92] |
| Gypenosides | BALB/c mice: xenografted with murine colorectal cancer CT-26 cells |
75 % (tumor size, 25 mg/kg for 19 days) 55 % (tumor size, 50 mg/kg for 19 days) 26 % (tumor size, 50 mg/kg + 5 mg/kg 5-Fu for 19 days) | [93] |
| Gypenosides | Apc Min/+ mice: intestinal neoplasia model |
66.06 % (polyps number, 500 mg/kg for 4 weeks) 59.92 % (polyps number, 750 mg/kg for 4 weeks) | [94] |
| Gypenosides | Apc Min/+ mice: intestinal neoplasia model | 59.32 % (polyps number, 500 mg/kg for 8 weeks) | [95] |
| Polysaccharide | BALB/c mice: xenografted with murine S180 sarcoma cells |
62.77 % (tumor size, 100 mg/kg for 14 days) 59.24 % (tumor size, 200 mg/kg for 14 days) | [97] |
| Polysaccharide | ICR mice: xenografted with mouse hepatoma H22 cells |
62.89 % (tumor size, 50 mg/kg for 10 days) 49.22 % (tumor size, 200 mg/kg for 10 days) | [20] |